<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02541045</url>
  </required_header>
  <id_info>
    <org_study_id>DI/15/108/03/48</org_study_id>
    <nct_id>NCT02541045</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis</brief_title>
  <official_title>Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General de Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital General de Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy of metadoxine as a therapy for patients
      with biopsy-proven non-alcoholic steatohepatitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type and design of the study: A randomized, placebo-controlled, double-blind, clinical trial
      to evaluate the efficacy of metadoxine as a therapy in patients with biopsy-proven
      nonalcoholic steatohepatitis.

      Population: Non-diabetic patients with nonalcoholic steatohepatitis diagnosed by liver biopsy
      through the &quot;nonalcoholic fatty liver disease activity score&quot; (NAS)&gt; 3.

      Sample size: Considering a difference of at least 30% between groups, a confidence level of
      95% (two-sided, significance 0.05), a statistical power of 80%, and an additional 20% for
      possible losses, we need 54 patients per group.

      Variables:

      Independent: Treatment group (metadoxine / placebo).

      Dependents:

        -  &quot;Nonalcoholic fatty liver disease activity score&quot; (NAS):0 a 8

        -  Degree of liver steatosis: 0 a 3

        -  Degree of lobular inflammation: 0 a 3

        -  Degree of ballooning: 0 a 2

        -  Degree of fibrosis: 0 a 2

        -  Weight: Kg

        -  Body mass index: Kg/m2

        -  Waist circumference: cm

        -  Serum alanine aminotransferase: U/L

        -  Serum aspartate aminotransferase: U/L

      Methods:

      Those meeting the selection criteria will be invited to participate in this study, those who
      agree to participate must sign the consent form and will be randomized to placebo or
      metadoxine group. The duration of the therapy will be 6 months and after this period a second
      liver biopsy will be performed to assessed the improvement on liver histology.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvement in the degree of non-alcoholic fatty liver disease score (NAS)</measure>
    <time_frame>6 months</time_frame>
    <description>Non-alcoholic fatty liver disease score (NAS) is an histological classification to assessed the severity of liver steatosis, lobular inflammation and ballooning in the liver biopsy. It is measured on a scale from 0 to 8</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>improvement in liver steatosis measured on a scale from 0 to 3</measure>
    <time_frame>6 months</time_frame>
    <description>Liver biopsy: measured on a scale from 0 to 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvement in lobular inflammation measured on a scale from 0 to 3</measure>
    <time_frame>6 months</time_frame>
    <description>Liver biopsy: measured on a scale from 0 to 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvement in ballooning measured on a scale from 0 to 2</measure>
    <time_frame>6 months</time_frame>
    <description>Liver biopsy: measured on a scale from 0 to 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvement in alanine aminotransferase serum levels</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvement in aspartate aminotransferase serum levels</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improvement in the degree of liver fibrosis measured on a scale from 0 to 2</measure>
    <time_frame>6 months</time_frame>
    <description>Liver biopsy: measured on a scale from 0 to 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to compare the occurrence of adverse effects between groups</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Non-alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Group 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Metadoxine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>therapy with metadoxine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metadoxine</intervention_name>
    <description>metadoxine 500mg tablets: 1 Tablet by mouth twice in day during 6 months</description>
    <arm_group_label>Group 2: Metadoxine</arm_group_label>
    <other_name>Abrixone, Metadoxil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo tablets: 1 Tablet by mouth twice in day during 6 months</description>
    <arm_group_label>Group 1: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-diabetic patients,

          -  Overweight or with obesity degrees I, II or III according to WHO criteria (BMI ≥ 25),

          -  With evidence of liver steatosis in the ultrasonography,

          -  With biopsy-proven nonalcoholic steatohepatitis, with ≥ 3 in the NAS score (at least 1
             point for liver steatosis, at least 1 point for lobular inflammation, and at least 1
             point for ballooning),

          -  With or without fibrosis in the liver biopsy, but if it is present must be ≤ 2 on a
             scale of 4, where 4 is equivalent to cirrhosis.

        Exclusion Criteria:

          -  Cirrhosis,

          -  Diabetes,

          -  Heavy alcohol intake ( ≥ 20 g / day), ≥ 8 points in the &quot;Alcohol Use Disorders
             Identification Test&quot; (AUDIT),

          -  Acute or chronic hepatitis C,

          -  Acute or chronic hepatitis B,

          -  Immunodeficiency acquired syndrome

          -  Pregnant women,

          -  In the last year, history of herbal consumption, total parenteral nutrition,
             amiodarone, methotrexate, hormonal contraceptives, steroids, tamoxifen, valproic acid
             or any other drug associated with the development of liver steatosis.

          -  Uncontrolled hypothyroidism or hyperthyroidism,

          -  Any uncontrolled chronic disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fatima Higuera-de la Tijera, MD, MSc.</last_name>
    <role>Study Director</role>
    <affiliation>Hospital General de México</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fatima Higuera-de la Tijera, MD, MSc.</last_name>
    <phone>015527892000</phone>
    <phone_ext>1523</phone_ext>
    <email>fatimahiguera@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alfredo I Servín-Caamaño, MD.</last_name>
    <phone>015527892000</phone>
    <phone_ext>1051</phone_ext>
    <email>draisc@yahoo.com.mx</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital General de México</name>
      <address>
        <city>Mexico City</city>
        <state>DF</state>
        <zip>06726</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fatima Higuera-de la Tijera, MD, MSc.</last_name>
      <phone>015527892000</phone>
      <phone_ext>1523</phone_ext>
      <email>fatimahiguera@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Alfredo I Servin-Caamaño, MD</last_name>
      <phone>015527892000</phone>
      <phone_ext>1051</phone_ext>
      <email>draisc@yahoo.com.mx</email>
    </contact_backup>
    <investigator>
      <last_name>Gerardo Aristi-Urista, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abraham Silva-Carmona, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rocio Enriquez-García, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alejandra Oropeza-Colomer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose A Vanegas-Herrera, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2015</study_first_submitted>
  <study_first_submitted_qc>September 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2015</study_first_posted>
  <last_update_submitted>August 15, 2016</last_update_submitted>
  <last_update_submitted_qc>August 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General de Mexico</investigator_affiliation>
    <investigator_full_name>MARIA DE FATIMA HIGUERA DE LA TIJERA</investigator_full_name>
    <investigator_title>MD, MSc.</investigator_title>
  </responsible_party>
  <keyword>non-alcoholic steatohepatitis</keyword>
  <keyword>metadoxine</keyword>
  <keyword>efficacy</keyword>
  <keyword>therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metadoxine</mesh_term>
    <mesh_term>Pyridoxine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

